source
- Novo’s IL-6 inhibitor ziltivekimab may target milder cardio-renal patients after Phase 3 missAt the American Heart Association meeting, investigators discussed new data on Novo Nordisk’s IL-6 inhibitor ziltivekimab, suggesting it could be studied in patients with less severe cardiovascular…
- Phase II success does not guarantee easy Phase III launch, says Thermo FisherPositive Phase II data often signals the start of Phase III planning, but the transition involves far more than simply adding patients and sites. When a trial expands into new countries, differenc…